

- Allan, A. L. (2010). *Metastasis In : Kuerer's breast surgical oncology*. Kuerer H R. Ed. New York. Mc Graw Hill : 27-40.
- Abigall, R. D. L. Javier M,T. (2005). *Serum Markers and Prognosis in Locally Advanced Breast Cancer*, *Tumori*. 91: 522-530.
- Alharbi, K. S. et al. (2022). *Role of Medicinal plant-derived Nutraceuticals as a potential target for the treatment of breast cancer*, *Journal of Food Biochemistry*. 46(12), pp. 1–18. doi:10.1111/jfbc.14387.
- American Society of Clinical Oncology (2023) 'Breast Cancer : Statistics'.
- Arnold, M. et al. (2022). *Current and future burden of breast cancer: Global statistics for 2020 and 2040*. *Breast Elsevier Ltd*, 66(August), pp. 15–23. doi:10.1016/j.breast.2022.08.010.
- Bray, F. Ferlay, J. Soerjomataram, I. (2018). *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. *CA Cancer J Clin*. 68: 394-424. doi: 10.3322/caac.21492
- Berg, J.M. Tymoczko, J.L. Stryer, L. (2002). *Exploring Proteins*. In : *Biochemistry* W.H. Freeman and Company. 137-194. doi: 10.1038/s41416-020-01200-0.
- Chan, P. F. Hamid, R. A. (2021). *An overview of breast cancer: Classification and related signaling pathways*. *Progress in Microbes and Molecular Biology*, 4(1). doi: 10.36877/pmmb.a0000194.
- Chang, Y. Zuka, M. Pinera, P.P. Astudillo, A. Mortimer, J. Berenson, J.R. & Deuel, T.F. (2007). *Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment*. *PNAS*. 104 (26) : 10888-10893. doi: 10.1073/pnas.0704366104
- Chatterjee, S. J. Caffrey, L. (2014). *Emerging role of cell polarity proteins in breast cancer progression and metastasis*. *Breast Cancer: Targets and Therapy*, 15–27. doi: 10.2147/BCTT.S43764
- Constantinos, M. Marina, K. et al. (2007). *Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer*. *Bentham Science Publishers Ltd, Greece* Volume 2, Number 2, 2007, pp. 175-36 (12). doi : <https://doi.org/10.2174/157489207780832405>
- W. W. (2008). *Buku Ajar Onkologi Klinis*, edisi 2. Fakultas edokteran Universitas Indonesia. Jakarta. h; 365-383.



Depkes RI. (2016). Situasi Penyakit Kanker. <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatinkanker.pdf>

DeVita, V. T., Jr., Lawrence, T. S., & Rosenberg, S. A. (2015). *Devita, Hellman, and Rosenberg's cancer. Principles & practice of oncology* (10th edition.) H : 230-221.

Deuel. Thomas, F. (2005). *Role of pleiotrophin in breast cancer*. <https://grantome.com/grant/NIH/R01-CA066029-08>

Ganguly, D. Schmidt, M.O. Coleman, M. et al. (2023). *Pleiotrophin drives a prometastatic immune niche in breast cancer*. *Journal of Experimental Medicine*. 220 (5) : 1-19. DOI:10.1084/jem.20220610

Ganguly, D. Schmidt, M. O. Coleman, M. et al. (2022). *Pleiotrophin drives a pro-metastatic immune niche within the breast tumor microenvironment* 220 (5) : 1-19. DOI:10.1084/jem.20220610

Ferlay, J. Soerjomataram, I. Dikshit, R. Eser, S. Mathers, C. Rebelo, M. Parkin, D. M. Forman, D. & Bray. F. (2014). *Cancer incidence and mortality worldwide: Sources, methods and major patterns in Globocan 2012*. *Int. J. Cancer*, 136, 359-386. doi: 10.1002/ijc.29210

Jemal, A. Bray, F. Ferlay, J. et al. (2011). *Global cancer statistics*. *CA Cancer J Clin*. 61: 69-90. doi: 10.3322/caac.20107

Jiupeng, Z. Yuanli, Y. et al. (2018). *A meta-analysis on the role of pleiotrophin (PTN) as a prognostic factor in cancer*. *Xi'an Chest Hospital, Xi'an, Shaanxi Province, China*. 14;13(11):e0207473.doi: 10.1371/journal.pone.0207473

Kementrian Kesehatan Republik Indonesia (2018). *Panduan Penatalaksanaan Kanker Payudara*. <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf> - Diakses maret 2022



V. Abbas, A.K. Aster, J. C. (2018). *Neoplasia*. In: *Robbins Basic pathology*. Kumar V et.al., ed. Philadelphia. Elsevier. 189-242.

- Lawson C.D. & Ridley A.J. 2017. *Rho GTPase signaling complexes in cell migration and invasion*. J. Cell Biol., 217,2,447-457. DOI: 10.1083/jcb.201612069
- Liu, S. et al. (2021). *Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer*, *British Journal of Cancer*. Springer US, 124(5), pp. 896–900. doi: 10.1038/s41416-020-01200-0.
- Ma, J. Kong, Y. Nan, H. Qu, S. Fu, X. et al. (2017). *Pleiotrophin as a potential biomarker in breast cancer patients*. *Clin Chim Acta* 466: 6–12. <https://doi.org/10.1016/j.cca.2016.12.030> PMID: 28041942
- Malekian, S. Rahmati, M. Sari, S. et al. (2020). *Expression of Diverse Angiogenesis Factor in Different Stages of the 4T1 Tumor as a Mouse Model of Triple-Negative Breast Cancer*. *National Library of Medicine*. 10 (2) : 323-328. doi: 10.34172/apb.2020.039
- Morrow, M. Burstein, H. J. Harris, J. R. (2015). *Malignant Tumors of the Breast*. In: *Cancer Principle and practice of oncology*. 10th ed. Devita V T, Lawrence T S, Rosenberg S A. Philadelphia. Walter Kluwer. 1117-1156. doi: 10.5114/wo.2013.37543
- Montesinos, P.B. Teruel, P.M. Arminan, A. et.al. (2021). *The past, present, and future of breast cancer models for nanomedicine development*. *Elveiser*. *Spanyol*. 173:306-330. doi: 10.1016/j.addr.2021.03.018.
- Olivia, J.S. Bay, B. Yip, G. Yu, Y. (2012). *Breast cancer metastasis*. *Cancer Genomics Proteomics*. ;9(5):311-20. PMID: 22990110
- Papadimitriou, E., Mourkogianni, E., Ntenekou, D., et al (2022) On the role of pleiotrophin and its receptors in development and angiogenesis. *Int J Dev Biol*. 66 : 115-124. doi: 10.1387/ijdb.210122ep
- Papadimitriou, E. et al. (2016). *Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer*. *Biochim Biophys Acta*,. 1866(2): p. 252–265. doi: [10.1016/j.bbcan.2016.09.007](https://doi.org/10.1016/j.bbcan.2016.09.007)
- Pandya, H. Murray, E. Pollok, K. Renbarger, L. (2016). *The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches*. *Journal of Immunology Research*. doi: 10.1155/2016/4273943



Perez, P. Yunchao, C. et al. (2008). *Pleiotrophin, A Multifunctional tumor Promoter Through Induction of Tumor Angiogenesis*,

*Remodeling of the Tumor Microenvironment, and Activation of Stromal Fibroblasts.* The Scripps Research Institute, La Jolla and Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA. (23):2877-83. doi: 10.4161/cc.6.23.5090.

Polyak, K. (2007) 'Breast cancer: Origins and evolution', *Journal of Clinical Investigation*, 117(11), pp. 3155–3163. doi: 10.1172/JCI33295.

Rakha, E.A, Reis-Filho, J.S., Baehner, F., Dabbs, D.J., Decker, T., Eusebi, V., and Ellis, I.O. (2010). *Breast Cancer Prognostic Classification in the Molecular Era : The Role of Histological Grade.* *Breast Cancer Research : BCR*, 12(4), 207. <https://doi.org/10.1186/bcr2607>

Sampepajung, D. (2010). *Kanker payudara di Indonesia, masalah dan penanggulangannya.* Naskah pidato pada acara pengukuhan sebagai guru besar bidang ilmu bedah onkologi Fakultas Kedokteran Universitas Hasanuddin, Makassar..

Sung, H. et al. (2021). 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.

Tayyab, A. (2021). *Identification of non-invasive biomarkers for early detection of breast cancer: A Review.* *J Clinical Oncology Research and Reports*, 2(1); Doi: 10.31579/2693-4787/017

Tsuji, W. Plock, J. A. (2017). *Breast Cancer Metastasis.* Introduction to Cancer Metastasis. pp. 13–31. doi: 10.1016/B978-0-12-804003-4.00002-5.

Wang, Xu. (2020). *Pleiotrophin: Activity and Mechanism.* *Advances in Clinical Chemistry.* USA. :98:51-89. Pages 51-89, doi: 10.1016/bs.acc.2020.02.003.

Wu, T. Fu, L. (2019). *ALK Tyrosine Kinase Inhibitors in Drugs Sensitization.* *China.* National Library Of Medicine. 12: 6481–6495. doi: 10.2147/OTT.S185115



et al. (2018). *A meta-Analysis on the role of pleiotrophin (PTN) as prognostic factor in cancer.* *PLoS ONE*, 13(11), pp. 1–14. doi: 10.1371/journal.pone.0207473